Viyash Scientific Limited (formerly known as Sequent Scientific Limited) has completed the allotment of 4,83,333 equity shares under its Employee Stock Option Plan 2020 scheme. The company informed stock exchanges about this development through a regulatory filing dated January 29, 2026.

ESOP Allotment Details

The Nomination and Remuneration Committee approved the allotment through a resolution passed by circulation on January 29, 2026. The shares were issued to eligible employees under the SeQuent ESOP 2020 scheme.

Impact on Share Capital

The allotment has resulted in an increase in the company's issued and paid-up equity share capital. The newly allotted shares will rank pari passu in all respects with the existing equity shares of the company.

Corporate Information

Viyash Scientific Limited, formerly known as Sequent Scientific Limited, is headquartered in Hyderabad, Telangana. The company trades on both BSE and NSE with scrip code 512529 and symbol VIYASH respectively. The regulatory filing was signed by Yoshita Vora, Company Secretary and Compliance Officer, confirming the completion of the ESOP allotment process.

The company has requested both stock exchanges to take note of this allotment and update their records accordingly. This ESOP allotment represents part of the company's employee incentive program designed to align employee interests with shareholder value creation.

Sequent Scientific Limited, now operating as Viyash Scientific Limited, has entered into a strategic partnership with Boehringer Ingelheim India Private Limited to expand its presence in India's companion animal healthcare market. The partnership, executed through Viyash Scientific's wholly owned subsidiary Alivira Animal Health Limited, focuses on distribution and promotion of Boehringer Ingelheim's companion animal products portfolio across India.

Strategic Partnership Details

The collaboration is designed to capture growing opportunities in India's pet healthcare market, which is experiencing significant growth driven by increased pet ownership, rising awareness of preventive care, and growing emphasis on animal well-being across the country.

Leadership Perspectives

Dr. Haribabu Bodepudi, MD & Group CEO of Viyash Scientific Limited, emphasized the significance of this partnership: "This represents an important milestone in Viyash Scientific's journey to become a key player in the companion animal segment. India offers tremendous opportunities for innovative medicines which cater to the medical needs of our pets."

Dr. Vinod Gopal, Country Head, Animal Health at Boehringer Ingelheim India, highlighted the strategic alignment: "This partnership aligns with our long-term growth strategy for the animal health business in India and enables us to serve our customers with greater clarity, consistency, and care."

Market Expansion Strategy

The partnership leverages the complementary strengths of both organizations:

• Alivira's Capabilities: Extensive geographical reach and on-ground capabilities across India
• Boehringer Ingelheim's Portfolio: Differentiated companion animal products and robust pipeline
• Combined Focus: Enhanced market reach, improved access, and execution excellence

Company Background

Viyash Scientific Limited, formerly known as Sequent Scientific Limited, is among the top 25 Animal Health companies globally. The company operates as an integrated pharmaceutical company with over 3,000 employees, serving customers in over 100 countries. The group maintains manufacturing, R&D, and distribution operations across India, Spain, Brazil, Turkey, and USA, with approvals from international regulatory bodies including USFDA, EUGMP, WHO, and TGA.

Boehringer Ingelheim, established in India in 2003, operates as a biopharmaceutical company active in both human and animal health, with more than 53,500 employees serving over 130 markets globally. The company focuses on developing innovative therapies in areas of high unmet medical need, with key therapy areas including diabetes, cardiovascular, and respiratory conditions.